Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel–cyclophosphamide chemotherapy for breast cancer: a systematic review Ricardo FernandesSasha MazzarelloMark Clemons Review 25 October 2016 Pages: 1 - 10
Can we prevent BRCA1-associated breast cancer by RANKL inhibition? Joanne KotsopoulosChristian SingerSteven A. Narod Review 25 October 2016 Pages: 11 - 16
Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast Michael J. CampbellFrederick BaehnerLaura Esserman Preclinical study 26 October 2016 Pages: 17 - 28
Up-regulation of cathepsin S expression by HSP90 and 5-HT7 receptor-dependent serotonin signaling correlates with triple negativity of human breast cancer Jaya GautamYoung Kyung BaeJung-Ae Kim Preclinical study 27 October 2016 Pages: 29 - 40
Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer Dominic AmaraDenise M. WolfChristina Yau Preclinical study 04 November 2016 Pages: 41 - 50
Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients Nicole JanssenSotirios P. FortisChristopher Shipp Clinical trial 27 October 2016 Pages: 51 - 62
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study Nadia HarbeckSteffen SaupeOn behalf of the PELICAN Investigators Clinical trial Open access 31 October 2016 Pages: 63 - 72
Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis Clémentine JankowskiS. GuiuF. Reyal Clinical trial 02 November 2016 Pages: 73 - 81
Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer Chun WangZhaomei MuHushan Yang Epidemiology 22 October 2016 Pages: 83 - 94
Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer Haeyoung KimDae-Yeon ChoSeok Won Kim Epidemiology 25 October 2016 Pages: 95 - 102
The impact of nodal micrometastasis on mortality among women with early-stage breast cancer Javaid IqbalOphira GinsburgSteven A. Narod Epidemiology 28 October 2016 Pages: 103 - 115
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3 Yosr HamdiPenny SoucyJacques Simard Epidemiology Open access 28 October 2016 Pages: 117 - 134
Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel Olivia MoranDina NikitinaJoanne Kotsopoulos Epidemiology 31 October 2016 Pages: 135 - 142
3D conformal radiotherapy is not associated with the long-term cardiac mortality in breast cancer patients: a retrospective cohort study in Germany (PASSOS-Heart Study) Hiltrud MerzenichDetlef BartkowiakMaria Blettner Epidemiology 01 November 2016 Pages: 143 - 152
A model for individualized risk prediction of contralateral breast cancer Marzana ChowdhuryDavid EuhusPankaj K. Choudhary Epidemiology 04 November 2016 Pages: 153 - 160
Characteristics associated with nonadherence to medications for hypertension, diabetes, and dyslipidemia among breast cancer survivors Gregory S. CalipJoann G. ElmoreDenise M. Boudreau Epidemiology 08 November 2016 Pages: 161 - 172
Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy Lior Z. BraunsteinAlphonse G. TaghianJay R. Harris Brief Report 03 November 2016 Pages: 173 - 179
A prospective study of peripheral blood DNA methylation at RPTOR, MGRN1 and RAPSN and risk of breast cancer Pierre-Antoine DuguéRoger L. MilneMelissa C. Southey Letter to the Editor 24 October 2016 Pages: 181 - 183
